Arvinas price target lowered to $10 from $16 at BTIG

BTIG lowered the firm’s price target on Arvinas (ARVN) to $10 from $16 and keeps a Buy rating on the shares. The company provided an update on its collaboration agreement with Pfizer (PFE) for vepdegestrant, noting the two will jointly select a third party for outl-icensing and commercialization, the analyst tells investors in a research note. The firm says Arvinas management is optimistic on finding a new partner before the June 2026 FDA action note, but highlights the “very tight timeline.” BTIG views the news as a “reset” for Arvinas which provides an opportunity to focus on its internal programs for oncology and neuroscience. It sees an attractive entry point for the shares.